Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 67484703

Drug Profile

JNJ 67484703

Alternative Names: JNJ-4703; JNJ-67484703

Latest Information Update: 11 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Class Anti-inflammatories; Antibodies; Antirheumatics; Skin disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Rheumatoid arthritis; Sjogren's syndrome; Ulcerative colitis

Most Recent Events

  • 31 Mar 2024 Janssen Research and Development completes a phase II clinical trial in Sjogren's syndrome, Ulcerative colitis (Treatment experienced) and Rheumatoid arthritis (Treatment experienced) in United Kingdom (SC, Injection) (ISRCTN31164692) (EudraCT2021-005998-13)
  • 18 May 2023 Janssen Research & Development completes a phase I trial in Rheumatoid arthritis (Treatment-experienced) in Ukraine, Georgia, USA (Parenteral) (NCT04985812)
  • 02 Feb 2023 Phase-II clinical trials in Atopic dermatitis (In adults, In the elderly) in Germany (SC) (EudraCT2022-001528-14)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top